首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Research on Effect and Mechanism of Xuefu Zhuyu Decoction on CHD Based on Meta-Analysis and Network Pharmacology
【24h】

Research on Effect and Mechanism of Xuefu Zhuyu Decoction on CHD Based on Meta-Analysis and Network Pharmacology

机译:基于Meta分析和网络药理学的Xuefu Buuyu汤对CHD的效果和机制研究

获取原文
获取外文期刊封面目录资料

摘要

Xuefu Zhuyu Decoction (XFZY) is an ancient compound widely used in the treatment of coronary heart disease. However, its efficacy evaluation is not complete and its mechanism of action is not clear enough. In an attempt to address these problems, the efficacy was evaluated by meta-analysis and the mechanism was elucidated by the network pharmacology method. We systematically searched relevant studies in PubMed, Chinese National Knowledge Infrastructure Database (CNKI), Cochrane Library, Wanfang Data, and other databases from 2007 to 2019. The association between XFZY treatment and CHD was estimated by risk ratio (RR) and corresponding 95% confidence intervals (95% CIs). The compounds and the potential protein targets of XFZY were obtained from TCMSP, and active compounds were selected according to their oral bioavailability and drug similarity. The potential genes of coronary heart disease were obtained from TTD, OMIM, and GeneCards. The potential pathways related to genes were determined by GO and KEGG pathway enrichment analyses. The compound-target and compound-target-pathway networks were constructed. Molecular docking validates the component and the target. A total of 21 studies including 1844 patients were enrolled in the present meta-analysis, indicating that XFZY has a greater beneficial on total effect (fixed effect RR?=?1.30; 95% Cl: 1.24–1.36; ; I 2 ?=?0.0%) and electrocardiogram efficacy (fixed effect RR?=?1.40; 95% Cl: 1.26–1.56; ; I 2 ?=?0.0%) compared with the control group. A total of 1342 components in XFZY were obtained, among which, 241 were chosen as bioactive components. GO and KEGG analyses got top 10 significantly enriched terms and 10 enriched pathways. The C-T network included 192 compounds and 3085 targets, whereas the C-T-P network included 10 compounds, 109 targets, and 5 pathways. There was a good binding activity between the components and the targets. XFZY has the curative effect on coronary heart disease, and its mechanism is related to 10 compounds, 10 core targets, and 5 pathways.
机译:薛福株汤(XFZY)是一种广泛应用于治疗冠心病的古老化合物。但是,它的功效评估不完整,其行动机制尚不清楚。为了解决这些问题,通过荟萃分析评估疗效,并通过网络药理学方法阐明该机制。从2007年至2019年系统地搜索了PubMed,中国国家知识基础设施数据库(CNKI),Cochrane图书馆,万方数据和其他数据库的相关研究。XFZY治疗与CHD之间的关联受风险比(RR)估算,相应的95%置信区间(95%CIS)。 XFZY的化合物和潜在的蛋白质靶标是从TCMSP获得的,并根据其口服生物利用度和药物相似性选择活性化合物。从TTD,OMIM和Genecards获得冠心病的潜在基因。通过GO和KEGG途径富集分析确定与基因相关的潜在途径。构建复合靶和复合靶途径网络。分子对接验证组分和目标。总共21项研究包括1844名患者的患者,表明XFZY对总效果有更大的有益(固定效应RR?=?1.30; 95%CL:1.24-1.36;; I 2? 0.0%)和心电图功效(固定效果Rr?= 1.40; 95%Cl:1.26-1.56;;与对照组相比,I 2?= 0.0%)。获得XFZY中总共1342个组分,其中选择了241个作为生物活性成分。 Go和Kegg分析得到了最重要的10个富集的术语和10个富集的途径。 C-T网络包括192种化合物和3085个靶标,而C-T-P网络包括10个化合物,109个靶标和5个途径。组分和目标之间存在良好的结合活动。 Xfzy具有对冠心病的疗效,其机制与10种化合物,10个核心靶标和5个途径有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号